HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cindy Lamendola Selected Research

Overweight

1/2017Effect of Pioglitazone on Cardiometabolic Risk in Patients With Obstructive Sleep Apnea.
1/2016Does enhanced insulin sensitivity improve sleep measures in patients with obstructive sleep apnea: a randomized, placebo-controlled pilot study.
12/2014T-cell profile in adipose tissue is associated with insulin resistance and systemic inflammation in humans.
3/2014Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study.
10/2013Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes.
12/2011Use of a two-stage insulin infusion study to assess the relationship between insulin suppression of lipolysis and insulin-mediated glucose uptake in overweight/obese, nondiabetic women.
11/2011Preferential fat deposition in subcutaneous versus visceral depots is associated with insulin sensitivity.
11/2009Plasma glucose and insulin regulation is abnormal following gastric bypass surgery with or without neuroglycopenia.
7/2008Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects.
1/2008Clinical experience with a relatively low carbohydrate, calorie-restricted diet improves insulin sensitivity and associated metabolic abnormalities in overweight, insulin resistant South Asian Indian women.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Cindy Lamendola Research Topics

Disease

40Insulin Resistance
11/2021 - 03/2002
17Cardiovascular Diseases (Cardiovascular Disease)
11/2021 - 03/2002
14Overweight
01/2017 - 11/2003
11Weight Loss (Weight Reduction)
04/2017 - 12/2002
10Obesity
12/2014 - 12/2002
8Type 2 Diabetes Mellitus (MODY)
11/2021 - 10/2002
6Hyperinsulinism (Hyperinsulinemia)
04/2017 - 04/2004
6Metabolic Syndrome (Dysmetabolic Syndrome X)
07/2015 - 03/2002
5Dyslipidemias (Dyslipidemia)
01/2008 - 10/2002
4Obstructive Sleep Apnea
01/2017 - 05/2015
3Prediabetic State (Prediabetes)
11/2021 - 10/2013
2Glucose Intolerance
03/2014 - 04/2007
2Inflammation (Inflammations)
10/2013 - 12/2006
2Hypoglycemia (Reactive Hypoglycemia)
08/2010 - 11/2009
2Hypertension (High Blood Pressure)
09/2004 - 03/2002
1Body Weight Changes
11/2021
1Polycystic Ovary Syndrome (Syndrome, Stein-Leventhal)
04/2017
1Apnea
01/2016
1Hypoxia (Hypoxemia)
05/2015
1Nausea
03/2014
1Prehypertension
01/2011
1Hyperplasia
08/2010
1Weight Gain
06/2010
1Essential Hypertension
01/2009
1Coronary Disease (Coronary Heart Disease)
07/2007
1Abdominal Obesity
07/2007
1Non-alcoholic Fatty Liver Disease
05/2007
1Body Weight (Weight, Body)
04/2004
1Rhabdomyolysis
10/2002
1Hypercholesterolemia
10/2002

Drug/Important Bio-Agent (IBA)

42Insulin (Novolin)FDA Link
11/2021 - 03/2002
31Glucose (Dextrose)FDA LinkGeneric
11/2021 - 03/2002
15Triglycerides (Triacylglycerol)IBA
01/2017 - 03/2002
11HDL CholesterolIBA
01/2017 - 03/2002
9Lipoproteins (Lipoprotein)IBA
01/2017 - 10/2002
5LipidsIBA
07/2008 - 10/2002
4Rosiglitazone (Avandia)FDA Link
07/2008 - 03/2002
4CarbohydratesIBA
01/2008 - 10/2006
4AdiponectinIBA
12/2006 - 03/2004
4Octreotide (Sandostatin)FDA LinkGeneric
01/2005 - 09/2002
3Pioglitazone (Actos)FDA Link
01/2017 - 08/2008
3Pharmaceutical PreparationsIBA
08/2008 - 10/2002
2oxidized low density lipoproteinIBA
11/2021 - 08/2005
2Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
11/2021 - 10/2002
2LDL CholesterolIBA
11/2021 - 03/2002
2Unsaturated FatsIBA
04/2017 - 10/2006
2Proteins (Proteins, Gene)FDA Link
04/2017 - 05/2007
2C-Reactive ProteinIBA
01/2017 - 12/2002
2LiraglutideFDA Link
03/2014 - 10/2013
2N,N-dimethylarginine (asymmetric dimethylarginine)IBA
05/2006 - 03/2002
2Gemfibrozil (Lopid)FDA LinkGeneric
01/2005 - 10/2002
1Atorvastatin (Lipitor)FDA Link
11/2021
1Dihydrotachysterol (AT 10)IBA
11/2021
1Dietary Carbohydrates (Carbohydrate, Dietary)IBA
04/2017
1Apolipoprotein A-I (Apolipoprotein A1)IBA
01/2017
1alpha-2-HS-GlycoproteinIBA
07/2015
1Oxygen (Dioxygen)IBA
05/2015
1Biological ProductsIBA
12/2014
1Interleukin-10 (Interleukin 10)IBA
12/2014
1salicylsalicylic acid (salsalate)IBA
07/2014
1Glycerol (Glycerine)FDA LinkGeneric
12/2011
1Hypoglycemic Agents (Hypoglycemics)IBA
08/2010
1Risperidone (Risperdal Consta)FDA LinkGeneric
06/2010
1Olanzapine (Zyprexa)FDA Link
06/2010
1Aripiprazole (Abilify)FDA Link
06/2010
1Antipsychotic Agents (Antipsychotics)IBA
06/2010
1N 30IBA
11/2009
1Fenofibrate (CiL)FDA LinkGeneric
07/2008
1Nonesterified Fatty Acids (NEFA)IBA
07/2008
1Alanine Transaminase (SGPT)IBA
05/2007
12,4-thiazolidinedione (thiazolidinedione)IBA
01/2006
1ApolipoproteinsIBA
01/2005
1lipoprotein cholesterolIBA
01/2005
1Rosuvastatin Calcium (Crestor)FDA Link
01/2005
1Adenosine Triphosphate (ATP)IBA
05/2004
1Hormones (Hormone)IBA
04/2004
1GhrelinIBA
04/2004
1Metformin (Glucophage)FDA LinkGeneric
02/2004
1Biomarkers (Surrogate Marker)IBA
09/2003
1Oxidoreductases (Dehydrogenase)IBA
10/2002
1fibric acidIBA
10/2002
1Fibric Acids (Fibrates)IBA
10/2002
1glutaryl-coenzyme A (glutaryl-CoA)IBA
10/2002
1Nitric Oxide Synthase (NO Synthase)IBA
03/2002

Therapy/Procedure

3Caloric Restriction
07/2008 - 10/2006
3Therapeutics
01/2006 - 10/2002
2Gastric Bypass (Roux-en-Y Gastric Bypass)
08/2010 - 11/2009
2Fat-Restricted Diet (Diet, Fat Restricted)
05/2007 - 10/2006
1Carbohydrate-Restricted Diet (Low Carbohydrate Diet)
01/2008
1Aftercare (After-Treatment)
01/2006
1Reducing Diet
09/2004
1Glycemic Control
02/2004